Genetic Analysis of PIK3CA Status in Tumor Cells

Definitions
Mutations to the Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene are suggested to be linked to the development of several cancers including breast cancer, colorectal cancer, endometrial cancer, gastric cancer and lung cancer.

Related Medical Guidelines
Gene Expression Profiling
Genetic Counseling and Testing

Guideline
Analysis of PIK3CA status in tumor cells is considered investigational and not medically necessary for all indications. *

* Note: Pharmacogenetic testing (using an FDA approved companion diagnostic test) may be considered medically necessary for members with PIK3CA-mutated, advanced or metastatic breast cancer, who are under consideration for treatment with Piqray® (alpelisib), as determined through the Pharmacy preauthorization process.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81404</td>
<td>Molecular pathology procedure, Level 5 (eg. analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>

Revision History
Feb. 14, 2020 — added PIK3CA pharmacogenetic testing for Piqray consideration as a covered exception.

References


